Connor, Clark & Lunn Investment Management Ltd. Arcturus Therapeutics Holdings Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$24.35 - $44.39 $1 Million - $1.83 Million	-41,115 Reduced 35.46%	74,830 $1.82 Million
Q1 2024 May 09, 2024	BUY	$31.23 - $42.99 $506,019 - $696,566	16,203 Added 16.24%	115,945 $3.92 Million
Q4 2023 Feb 09, 2024	BUY	$17.71 - $32.97 $1.14 Million - $2.13 Million	64,520 Added 183.18%	99,742 $3.14 Million
Q3 2023 Nov 13, 2023	SELL	$25.44 - $37.35 $214,001 - $314,188	-8,412 Reduced 19.28%	35,222 $899,000
Q2 2023 Aug 10, 2023	BUY	$23.94 - $32.36 $1.04 Million - $1.41 Million	43,634 New	43,634 $1.25 Million
Q2 2022 Aug 05, 2022	SELL	$12.26 - $31.17 $433,072 - $1.1 Million	-35,324 Reduced 64.7%	19,276 $303,000
Q1 2022 May 12, 2022	SELL	$17.64 - $39.57 $587,394 - $1.32 Million	-33,299 Reduced 37.88%	54,600 $1.47 Million
Q4 2021 Feb 10, 2022	BUY	$34.2 - $47.56 $335,741 - $466,896	9,817 Added 12.57%	87,899 $3.25 Million
Q3 2021 Nov 12, 2021	BUY	$27.88 - $58.25 $2.18 Million - $4.55 Million	78,082 New	78,082 $3.73 Million

Others Institutions Holding ARCT

# of Institutions

177

Shares Held

25.7M

Call Options Held

195K

Put Options Held

133K

Federated Hermes, Inc. Pittsburgh, PA

4.69M
Shares

$80.4 Million
0.25% of portfolio
Black Rock Inc. New York, NY

2.65M
Shares

$45.4 Million
0.0% of portfolio
Nikko Asset Management Americas, Inc.

2.32M
Shares

$39.6 Million
0.62% of portfolio
Sumitomo Mitsui Trust Holdings, Inc.

2.28M
Shares

$39 Million
0.04% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

2.1M
Shares

$36 Million
0.46% of portfolio

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $455M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account